SUMMARY -Angiogenesis is essential for the development, growth and progression of tumors. Although vascular endothelial growth factor (VEGF) is a well-known proangiogenic factor, its impact on lymphoma has not yet been fully clarifi ed. Th e aim of this study was to evaluate VEGF-A expression and microvessel density (MVD) in aggressive lymphoma such as diff use large B-cell lymphoma (DLBCL), in indolent lymphomas such as low-grade follicular lymphoma (FL), and in lymph node reactive follicular hyperplasia (FH). In 80 prospective and retrospective cases (30 DLBCL, 30 FL and 20 FH), CD31 was analyzed by immunohistochemical staining assessing density of blood vessels, as well as the total number of CD31 positive endothelial cells. Th e results were compared with relevant clinical data. MVD was 85% in FH, followed by 60% in DLBCL and 43% in low-grade FL. VEGF-A was signifi cantly higher in DLBCL than in low-grade FL and FH. A statistically signifi cant association of MVD and VEGF-A with the International Prognostic Index (IPI) was found in DLBCL. High MVD and VEGF-A expression was observed in DLBCL patients with high IPI, while there was no statistically signifi cant association between MVD and VEGF-A with the Follicular Lymphoma International Prognostic Index in low-grade FL. Our results suggested an important relationship between angiogenesis and high-grade lymphoma.
Introduction
Diff use large B-cell lymphoma not otherwise specifi ed (DLBCL) is the most common type of lymphoid tumor worldwide 1, 2 , and displays striking heterogeneity at clinical, genetic, and molecular levels. DLBCL was included both in the Revised European American Lymphoma (REAL) and World Health Organization (WHO) classifi cations aiming to describe all malignant lymphomas characterized by the large size of neoplastic cells, B-cell derivation, aggressive clinical presentation, and need for highly eff ective chemotherapy regimens 3, 4 . Follicular lymphoma (FL) is the second most common non-Hodgkin's lymphoma. Th is disease aff ects lymph nodes, and 50% of patients present with bone marrow infi ltration. However, the mechanisms involved in dissemination of the disease are still unclear 5 . FL is divided into three grades. Grades 1 and 2 are considered as lymphoma of low-grade malignancy 6 . Angiogenesis is the formation of new capillaries by outgrowth of endothelial cells from preexisting blood vessels 7 . Th e Vascular Endothelial Growth Factor/Vascular Endothelial Growth Factor Receptor (VEGF/ VEGFR) pathway is a key mediator of angiogenesis and VEGF-A acts as a potent tumor angiogenic factor. VEGF-A stimulates the growth of new blood vessels that provide tumors with oxygen and nutrients, which in turn determine the proliferative activity of the tumor. Expression of VEGF-A has been shown to be regulated at the transcriptional and translational levels 8, 9 . VEGF-A mediated angiogenesis has received considerable attention in the context of solid neoplasia, particularly with the clinical use of anti-VEGF-A antibodies and small molecule VEGFR inhibitors. More recently, the concept of tumor vascularity has been applied to hematolymphoid neoplasia, with studies quantifying microvessel density (MVD) in a variety of lymphomas 10, 11 . VEGF-A-mediated signaling has at least two potential roles in DLBCL, i.e. potentiation of angiogenesis, and potentiation of lymphoma cell proliferation and/or survival induced by autocrine VEGFR-mediated signaling [10] [11] [12] . Given the rapidly increasing availability of a variety of pharmaceuticals aimed at the VEGF-A pathway, the role of angiogenesis and VEGF-A signaling in DLBCL may be of great interest 10 . In non-Hodgkin's lymphomas, expression of angiogenic factors in cell lines 14 and neoplastic tissue [15] [16] [17] has been demonstrated. Although these studies suggest a role for angiogenesis in lymphomas, several questions remain unanswered. In addition, determination of MVD as a measure of the degree of angiogenesis is also one of the most examined parameters for angiogenesis in cancers 13 . It is not clear whether high MVD is associated with more aggressive lymphomas.
Th e aim of this study was to evaluate VEGF-A expression and MVD through expression of CD31 in endothelial cells in aggressive lymphomas such as DLBCL, in indolent lymphomas such as FL, and in lymph node reactive follicular hyperplasia (FH).
Furthermore, we analyzed the correlation of VEGF-A expression and MVD with the International Prognostic Index (IPI) in patients with DLBCL and Follicular Lymphoma International Prognostic Index (FLIPI) in patients with low-grade FL.
Materials and Methods
In our study, we evaluated VEGF-A and CD31 expression in 30 DLBCL, 30 FL and 20 FH cases diagnosed at the Institutes of Pathology, Faculty of Medicine, University of Prishtina and Faculty of Medicine, St. Cyril and Methodius University in Skopje.
Immunohistochemistry
Th e slides were deparaffi nized and rehydrated using standard procedures. Microwave heating was used for antigen retrieval and slides were then IHC stained using VEGF-A (A-20, 1:150 dilution; Santa Cruz Biotechnology Inc., USA, and CD31 (Clone JC70A, RTU; DAKO, Denmark) antibodies.
Protein expression of VEGF-A observed mainly in the cytoplasm of tumor cells was scored by combining the quantity score (percentage of positive stained cells) with the staining intensity score. All slides were analyzed independently by three pathologists. Th e quantity score ranged from 0 to 4: 0 = no immunoreactivity; 1 = <25% cells stained; 2 = 26%-50% cells stained; 3 = 51%-75% cells stained; and 4 = >76% cells stained. Th en, scores 1-4 were clustered into two groups: group I (scores 1 and 2) and group II (scores 3 and 4). Th e staining intensity was scored as: 0 (negative), 1 (weak positivity, seen at X400 magnifi cation), 2 (moderate, seen at X100 magnifi cation), and 3 (strong, seen at X40 magnifi cation). Th e fi nal score was obtained by multiplying the groups of quantity score and intensity, as follows: 0 = no immunoreactivity; 1 = low positivity (1%-50% of cells stained and seen at X400); 2 = moderate positivity (1%-50% cells stained and seen at X40x or >50% of cells stained and seen at X400); and 3 = high positivity (51%-100% cells stained and seen at X40).
Microvessel counting was used for angiogenesis assessment. CD31 immunostained tumor sections were scanned at low power magnifi cation (X100) to identify the areas with highest vascular density, so called 'hotspots'; then MVD was calculated as the mean value of CD31-positive cells and cell clusters in fi ve hot spots per section evaluated at X200 magnifi cation. Subse-quently, the MVD median value was used to classify each group of tumors in 'high' and 'low' MVD, by three independent observers to obtain consensus of categorization. Th e cut-off to categorize 'low' and 'high' MVD was a mean value of 10 blood vessels.
Prognostic index
Th e scoring systems, known as the IPI for DLBCL and FLIPI for FL, were used to compare results with clinical data. Th ree risk groups were categorized using the IPI and FLIPI scoring system: low risk, intermediate risk, and high risk 18, 19 .
Statistical analysis
Univariate analysis was performed to assess the percentage distribution and other main characteristics of single variables used in testing the hypotheses. Th e χ 2 -test was used to test diff erences and bivariate analysis to test correlation between categorical variables. All hypotheses were tested at the 0.05 level of signifi cance.
Results
Expression of VEGF-A in DLBCL was scored as follows: no immunoreactivity, 1 (3%) case; low positivity, 5 (17%) cases; moderate positivity 17 (57%) cases; and high positivity, 7 (23%) cases (Fig. 1) . However, in FL, VEGF-A expression was scored as follows: no immunoreactivity, 5 (17%) cases; low positivity, 4 (13%) cases; moderate positivity, 19 (63%) cases; and high positivity, 2 cases (7%). Lastly, in FH, 5 (25%) cases showed low positivity and 15 (50%) cases showed moderate positivity, while no cases showed high positivity (Table 1) .
Positive staining for CD31 was detectable in the membrane of endothelial cells in the stroma. Of 30 DLBCL cases, 18 (60%) showed high MVD and 12 (40%) showed low MVD, whereas in FL 13 (43%) cases showed high MVD and 17 (57%) cases showed low MVD. Control group (FH) was found to have a very high expression of MVD, as 16 (80%) cases showed high MVD and only 4 (20%) cases showed low MVD (Fig. 2) . Th e p-values obtained by the χ 2 -test yielded statistically signifi cant diff erences between the two groups of MVD (χ 2 =6.688, df=2, p=0.035) ( Table 2) .
Expression of VEGF-A was compared for the relationship with clinical data, i.e. prognostic index (IPI for DLBCL and FLIPI for FL). One DLBCL case without staining also had low IPI, 5 of 7 cases with high VEGF-A immunoreactivity had high IPI, an- 
Discussion
Angiogenesis is a multistep process playing a crucial role in the progression and metastasis of various tumors, including those of visceral organs and hematolymphoid malignancies 20 . Tumor angiogenesis has been well documented both in experimental and clinical studies, and the degree of angiogenesis was closely associated with tumor progression and shorter patient survival in many types of cancer 21, 22 . Non-Hodgkin's lymphomas are a diverse group of lymphoproliferative neoplasms with a variable clinical behavior and prognosis. Currently, lymphomas are classifi ed on the basis of morphology, immunology, genetic, and clinical features. Th e clinical stage of the lymphoma is the most important prognostic factor, apart from the histologic grade (indolent versus aggressive) 20 . Microvessel density measures lymphoma neovascularity generated in response to tumor cells, proangiogenic stromal cells, and infi ltrating benign T/B lymphocytes and myeloid cells within the tumor microenvironment. Th erefore, MVDs vary greatly among diff erent studies due to the heterogeneity of lymphoma stroma, the range of cell surface markers used for staining, and diff erences in scoring methodology. Th e clinical predictive value of MVD with respect to underlying lymphoma subtypes remains unclear 23 . In general, MVD scores trend highest in aggressive subtypes of lymphoma, compared with lower ones in indolent lymphoma. Gratzinger et al. report that average MVDs did correlate with the intensity of VEGF staining in a statistically signifi cant manner 24 . In another study, increasing MVD was found to be a poor prognostic indicator for overall but not progressionfree survival, and was independent of the IPI 25, . Koster et al. 11 found that in FL, high MVD as a variable of increased tumor vascularization was associated with a signifi cantly more favorable outcome in terms of both progression-free and overall survival 26 . Positive association between MVD and patient outcome is in contrast with the notion that in hematologic malignancies, as well as in solid tumors the increase of angiogenesis-associated variables is related to adverse prognosis 15, 22, 28 . Aggarwal et al. 20 found higher MVD in aggressive lymphoma such as peripheral T- Ganjo et al. 29, 30 report that antiangiogenic drugs have modest clinical activity in lymphomas as a single agent. Our results may suggest that antiangiogenic therapy could be active only in high-grade lymphomas expressing stronger VEGF.
Conclusion
Neoangiogenesis has been increasingly recognized to play potentially important pathogenic roles in lymphomagenesis. We can conclude that our results support the hypothesis that there is important relationship between angiogenesis and high-grade lymphoma. Also, there is signifi cant correlation with clinical data.
